Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8785206 | 0.87 | ZDHHC7 (0.39) | NOS1NOS3NOS2ZDHHC7KMT2A | |
| SCHEMBL27905397 | 0.85 | ZDHHC7 (0.46) | NOS1NOS3NOS2ZDHHC7KMT2A | |
| SCHEMBL9079671 | 0.85 | ZDHHC7 (0.46) | NOS1NOS3NOS2ZDHHC7KMT2A | |
| SCHEMBL3205535 | 0.83 | NOS1 (0.34) | NOS1NOS3NOS2KMT2AMEN1 | |
| SCHEMBL9691868 | 0.82 | ZDHHC7 (0.44) | NOS1NOS3NOS2ZDHHC7KMT2A | |
| SCHEMBL343267 | 0.82 | ZDHHC7 (0.36) | NOS1NOS3NOS2ZDHHC7KMT2A | |
| SCHEMBL9352351 | 0.79 | KMT2A (0.33) | NOS1NOS3NOS2ZDHHC7KMT2A | |
| SCHEMBL23552907 | 0.78 | HDAC3 (0.35) | NOS1NOS3NOS2ZDHHC7KMT2A | |
| SCHEMBL7329329 | 0.78 | ZDHHC7 (0.55) | ZDHHC7CA1CA2 | |
| SCHEMBL2007637 | 0.78 | ZDHHC7 (0.55) | ZDHHC7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117797258-A | Preparation method and application of photo-thermal synergistic chemical kinetics nano gel for resisting bacterial biofilm infection | 广东医科大学 | 2024-04-02 | — | — | CN | claimed |
| CN-117797258-A | Preparation method and application of photo-thermal synergistic chemical kinetics nano gel for resisting bacterial biofilm infection | 广东医科大学 | 2024-04-02 | — | — | CN | disclosed |
| EP-3873457-B1 | ISOSORBIDE-5-MONONITRATE DERIVATIVES AS POTENTIATORS OF VASODILATORY RELEASE OF NITRIC OXIDE IN HYPOXIA FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | COEURATIVE INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-111171014-B | Monocyclolactam compounds and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11779560-B2 | Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases | COEURATIVE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4126221-A2 | NOVEL METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | Coeurative, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115474429-A | Novel methods of treating COVID-19 and other infectious diseases using nitric oxide donor compounds | 合作股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-112771040-B | Monocyclic lactam compounds and uses thereof | 南京圣和药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20210346335-A1 | METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | COEURATIVE, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2001058889-A1 | TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-1115398-A1 | TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6218390-B1 | FOR LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, RELAXING LOWER URINARY TRACT TISSUE, THERAPY OF BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, CARDIAC ARRHYTHMIA, SYMPATHETIC MEDIATED PAIN, MIGRAINE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-17 | — | — | US | disclosed |
| WO-2000027817-A1 | OXAZOLIDINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000027827-A1 | OXAZOLIDINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000025782-A1 | DIHYDROPYRIDINONES AND PYRROLINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000016772-A1 | TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000006565-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779560-B2 | Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | BPGM, IL1B, WEE1 | NOS1 795/4885NOS3 2274/4885NOS2 1448/4885 |
| US-20210346335-A1 | METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.